生产企业：Regeneron Pharmaceuticals, Inc.
Trevogrumab is an investigational anti-GDF8 (myostatin) monoclonal antibody being developed by Regeneron Pharmaceuticals. It is currently in Phase 2 clinical trials (COURAGE) in combination with semaglutide for preserving lean mass in people with obesity.
Trevogrumab is an investigational anti-GDF8 (myostatin) monoclonal antibody being developed by Regeneron Pharmaceuticals. It is currently in Phase 2 clinical trials (COURAGE) in combination with semaglutide for preserving lean mass in people with obesity.
Trevogrumab is an anti-GDF8 (myostatin) monoclonal antibody. By inhibiting GDF8, a negative regulator of muscle growth, trevogrumab is designed to preserve lean muscle mass.
Trevogrumab is being investigated in combination with semaglutide for preserving lean mass in people with obesity, addressing muscle loss associated with GLP-1 receptor agonist-induced weight loss.
共 1 项相关疾病
